APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Insulin Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Insulin Biologics and Biosimilars Market Outlook and Growth Opportunities 2026

Report ID 174003510421 December 2025195 pages

Choose your research edition.

Industry ResearchInsulin Biologics and Biosimilars Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Insulin Biologics and Biosimilars Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Insulin Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Insulin Biologics and Biosimilars Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Insulin Biologics and Biosimilars Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Insulin Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Insulin Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Insulin Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Insulin Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Insulin Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Insulin Biologics and Biosimilars market include Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly, Wockhardt, United Laboratory, Geropharm, Gan&Lee and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Insulin Biologics and Biosimilars market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Insulin Biologics and Biosimilars and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Insulin Biologics and Biosimilars revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Insulin Biologics and Biosimilars market.

Insulin Biologics and Biosimilars Segment by Company

Tonghua Dongbao

Sanofi

Novo Nordisk

Eli Lilly

Wockhardt

United Laboratory

Geropharm

Gan&Lee

Biocon

Insulin Biologics and Biosimilars Segment by Type

Insulin Biologics

Insulin Biosimilars

Insulin Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Insulin Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Insulin Biologics and Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Insulin Biologics and Biosimilars key companies, revenue, market share, and recent developments.

3. To split the Insulin Biologics and Biosimilars breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Insulin Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Insulin Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Insulin Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Insulin Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Insulin Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Insulin Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Insulin Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Insulin Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Insulin Biologics and Biosimilars Industry Trends Table 2. Insulin Biologics and Biosimilars Industry Drivers Table 3. Insulin Biologics and Biosimilars Industry Opportunities and Challenges Table 4. Insulin Biologics and Biosimilars Industry Restraints Table 5. Global Insulin Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Insulin Biologics and Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Insulin Biologics and Biosimilars Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Insulin Biologics and Biosimilars Key Company Manufacturing Base & Headquarters Table 9. Global Insulin Biologics and Biosimilars Company, Product Type & Application Table 10. Global Insulin Biologics and Biosimilars Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Insulin Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Insulin Biologics Table 15. Significant Companies of Insulin Biosimilars Table 16. Global Insulin Biologics and Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Insulin Biologics and Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Insulin Biologics and Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Insulin Biologics and Biosimilars Sales Value Share by Type (2021-2026) Table 20. Global Insulin Biologics and Biosimilars Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Other Table 24. Global Insulin Biologics and Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Insulin Biologics and Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Insulin Biologics and Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Insulin Biologics and Biosimilars Sales Value Share by Application (2021-2026) Table 28. Global Insulin Biologics and Biosimilars Sales Value Share by Application (2027-2032) Table 29. Global Insulin Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Insulin Biologics and Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Insulin Biologics and Biosimilars Sales Value Share by Region (2021-2026) Table 32. Global Insulin Biologics and Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Insulin Biologics and Biosimilars Sales Value Share by Region (2027-2032) Table 34. Global Insulin Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Insulin Biologics and Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Insulin Biologics and Biosimilars Sales Value Market Share by Country (2021-2026) Table 37. Global Insulin Biologics and Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Insulin Biologics and Biosimilars Sales Value Market Share by Country (2027-2032) Table 39. Tonghua Dongbao Company Information Table 40. Tonghua Dongbao Business Overview Table 41. Tonghua Dongbao Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Tonghua Dongbao Insulin Biologics and Biosimilars Product Portfolio Table 43. Tonghua Dongbao Recent Development Table 44. Sanofi Company Information Table 45. Sanofi Business Overview Table 46. Sanofi Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sanofi Insulin Biologics and Biosimilars Product Portfolio Table 48. Sanofi Recent Development Table 49. Novo Nordisk Company Information Table 50. Novo Nordisk Business Overview Table 51. Novo Nordisk Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novo Nordisk Insulin Biologics and Biosimilars Product Portfolio Table 53. Novo Nordisk Recent Development Table 54. Eli Lilly Company Information Table 55. Eli Lilly Business Overview Table 56. Eli Lilly Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Eli Lilly Insulin Biologics and Biosimilars Product Portfolio Table 58. Eli Lilly Recent Development Table 59. Wockhardt Company Information Table 60. Wockhardt Business Overview Table 61. Wockhardt Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Wockhardt Insulin Biologics and Biosimilars Product Portfolio Table 63. Wockhardt Recent Development Table 64. United Laboratory Company Information Table 65. United Laboratory Business Overview Table 66. United Laboratory Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. United Laboratory Insulin Biologics and Biosimilars Product Portfolio Table 68. United Laboratory Recent Development Table 69. Geropharm Company Information Table 70. Geropharm Business Overview Table 71. Geropharm Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Geropharm Insulin Biologics and Biosimilars Product Portfolio Table 73. Geropharm Recent Development Table 74. Gan&Lee Company Information Table 75. Gan&Lee Business Overview Table 76. Gan&Lee Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Gan&Lee Insulin Biologics and Biosimilars Product Portfolio Table 78. Gan&Lee Recent Development Table 79. Biocon Company Information Table 80. Biocon Business Overview Table 81. Biocon Insulin Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Biocon Insulin Biologics and Biosimilars Product Portfolio Table 83. Biocon Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Insulin Biologics and Biosimilars Product Image Figure 2. Global Insulin Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Insulin Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Insulin Biologics and Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Insulin Biologics Image Figure 8. Insulin Biosimilars Image Figure 9. Global Insulin Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Insulin Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Insulin Biologics and Biosimilars Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Pharmacy Image Figure 14. Other Image Figure 15. Global Insulin Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Insulin Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Insulin Biologics and Biosimilars Sales Value Share by Application (2021-2032) Figure 18. Global Insulin Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Insulin Biologics and Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Insulin Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 21. North America Insulin Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Insulin Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Insulin Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Insulin Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Insulin Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Insulin Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 27. South America Insulin Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Insulin Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Insulin Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Biologics
  • Insulin Biosimilars
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • Wockhardt
  • United Laboratory
  • Geropharm
  • Gan&Lee
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Insulin Biologics and Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Insulin Biologics and Biosimilars Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Insulin Biologics and Biosimilars Market Dynamics
  1. 2.1 Insulin Biologics and Biosimilars Industry Trends
  2. 2.2 Insulin Biologics and Biosimilars Industry Drivers
  3. 2.3 Insulin Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Insulin Biologics and Biosimilars Industry Restraints
3 Insulin Biologics and Biosimilars Market by Company
  1. 3.1 Global Insulin Biologics and Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Insulin Biologics and Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Insulin Biologics and Biosimilars Company Ranking (2024-2026)
  4. 3.4 Global Insulin Biologics and Biosimilars Company Manufacturing Base and Headquarters
  5. 3.5 Global Insulin Biologics and Biosimilars Company Product Type and Application
  6. 3.6 Global Insulin Biologics and Biosimilars Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Insulin Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Insulin Biologics and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Insulin Biologics and Biosimilars Market by Type
  1. 4.1 Insulin Biologics and Biosimilars Type Introduction
  2. 4.1.1 Insulin Biologics
  3. 4.1.2 Insulin Biosimilars
  4. 4.2 Global Insulin Biologics and Biosimilars Sales Value by Type
  5. 4.2.1 Global Insulin Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Insulin Biologics and Biosimilars Sales Value by Type (2021-2032)
  7. 4.2.3 Global Insulin Biologics and Biosimilars Sales Value Share by Type (2021-2032)
5 Insulin Biologics and Biosimilars Market by Application
  1. 5.1 Insulin Biologics and Biosimilars Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Insulin Biologics and Biosimilars Sales Value by Application
  6. 5.2.1 Global Insulin Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Insulin Biologics and Biosimilars Sales Value by Application (2021-2032)
  8. 5.2.3 Global Insulin Biologics and Biosimilars Sales Value Share by Application (2021-2032)
6 Insulin Biologics and Biosimilars Regional Value Analysis
  1. 6.1 Global Insulin Biologics and Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Insulin Biologics and Biosimilars Sales Value by Region (2021-2032)
  3. 6.2.1 Global Insulin Biologics and Biosimilars Sales Value by Region: 2021-2026
  4. 6.2.2 Global Insulin Biologics and Biosimilars Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Insulin Biologics and Biosimilars Sales Value (2021-2032)
  7. 6.3.2 North America Insulin Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Insulin Biologics and Biosimilars Sales Value (2021-2032)
  10. 6.4.2 Europe Insulin Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Insulin Biologics and Biosimilars Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Insulin Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Insulin Biologics and Biosimilars Sales Value (2021-2032)
  16. 6.6.2 South America Insulin Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Insulin Biologics and Biosimilars Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Insulin Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Insulin Biologics and Biosimilars Country-level Value Analysis
  1. 7.1 Global Insulin Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Insulin Biologics and Biosimilars Sales Value by Country (2021-2032)
  3. 7.2.1 Global Insulin Biologics and Biosimilars Sales Value by Country (2021-2026)
  4. 7.2.2 Global Insulin Biologics and Biosimilars Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Insulin Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Insulin Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Insulin Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao
  2. 8.1.1 Tonghua Dongbao Company Information
  3. 8.1.2 Tonghua Dongbao Business Overview
  4. 8.1.3 Tonghua Dongbao Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao Insulin Biologics and Biosimilars Product Portfolio
  6. 8.1.5 Tonghua Dongbao Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Insulin Biologics and Biosimilars Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Insulin Biologics and Biosimilars Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Insulin Biologics and Biosimilars Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Wockhardt
  26. 8.5.1 Wockhardt Company Information
  27. 8.5.2 Wockhardt Business Overview
  28. 8.5.3 Wockhardt Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Wockhardt Insulin Biologics and Biosimilars Product Portfolio
  30. 8.5.5 Wockhardt Recent Developments
  31. 8.6 United Laboratory
  32. 8.6.1 United Laboratory Company Information
  33. 8.6.2 United Laboratory Business Overview
  34. 8.6.3 United Laboratory Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 8.6.4 United Laboratory Insulin Biologics and Biosimilars Product Portfolio
  36. 8.6.5 United Laboratory Recent Developments
  37. 8.7 Geropharm
  38. 8.7.1 Geropharm Company Information
  39. 8.7.2 Geropharm Business Overview
  40. 8.7.3 Geropharm Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Geropharm Insulin Biologics and Biosimilars Product Portfolio
  42. 8.7.5 Geropharm Recent Developments
  43. 8.8 Gan&Lee
  44. 8.8.1 Gan&Lee Company Information
  45. 8.8.2 Gan&Lee Business Overview
  46. 8.8.3 Gan&Lee Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gan&Lee Insulin Biologics and Biosimilars Product Portfolio
  48. 8.8.5 Gan&Lee Recent Developments
  49. 8.9 Biocon
  50. 8.9.1 Biocon Company Information
  51. 8.9.2 Biocon Business Overview
  52. 8.9.3 Biocon Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biocon Insulin Biologics and Biosimilars Product Portfolio
  54. 8.9.5 Biocon Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst